121 related articles for article (PubMed ID: 4546593)
1. [Cerebral and peripheral consumption of L-5-HTP in patients with manic, depressive or psychotic syndromes].
Gaillard JM; Eisenring JJ; Tissot R
Encephale; 1973; 62(5):395-407. PubMed ID: 4546593
[No Abstract] [Full Text] [Related]
2. [Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects].
Geissbuhler F; Eisenring JJ; Friedli P; Bartholini G; Tissot R
Encephale; 1972; 61(2):127-48. PubMed ID: 4634903
[No Abstract] [Full Text] [Related]
3. On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression.
Amamoto T; Sarai K
Hiroshima J Med Sci; 1976 Sep; 25(2-3):135-40. PubMed ID: 1088369
[No Abstract] [Full Text] [Related]
4. Metabolism of L-dihydroxyphenylalanine by patients with Parkinson's disease.
Tyce GM; Muenter MD; Owen CA
Mayo Clin Proc; 1970 Sep; 45(9):645-56. PubMed ID: 5311767
[No Abstract] [Full Text] [Related]
5. An unexpected effect of L-5 hydroxytryptophan-ethyl-ester combined with a peripheral decarboxylase inhibitor on human serum prolactin.
van Praag HM; Korf J; Lequin RM
Psychopharmacol Commun; 1976; 2(5-6):369-78. PubMed ID: 1088302
[TBL] [Abstract][Full Text] [Related]
6. The effect of oral 5-HTP administration on 5-HTP and 5-HT immunoreactivity in monoaminergic brain regions of rats.
Lynn-Bullock CP; Welshhans K; Pallas SL; Katz PS
J Chem Neuroanat; 2004 May; 27(2):129-38. PubMed ID: 15121217
[TBL] [Abstract][Full Text] [Related]
7. [Distribution and metabolism of 14C-dl-5-hydroxytryptophan in 2 carcinoid patients].
Waser PG; Wicker-Lüthi U; Wenzl H
Schweiz Med Wochenschr; 1970 May; 100(19):823-7. PubMed ID: 5312869
[No Abstract] [Full Text] [Related]
8. Measurement of 5-hydroxyindole compounds during L-5-HTP treatment in depressed patients.
Takahashi S; Takahashi R; Masumura I; Miike A
Folia Psychiatr Neurol Jpn; 1976; 30(4):461-73. PubMed ID: 1087913
[TBL] [Abstract][Full Text] [Related]
9. [Urinary excretion of 5-hydroxyindoleacetic acid and serum tryptophan and serotonin levels in patients with depression].
Pietruszewska I; Jasińska M; Lewicka-Wysocka H; Marcjan K; Stencka K
Psychiatr Pol; 1984; 18(1):9-16. PubMed ID: 6204348
[No Abstract] [Full Text] [Related]
10. Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase.
Bartholini G; Da Prada M; Pletscher A
J Pharm Pharmacol; 1968 Mar; 20(3):228-9. PubMed ID: 4385052
[No Abstract] [Full Text] [Related]
11. The effect of ethanol on the in vivo conversion of 5-HTP-14C to serotonin-14C, 5-hydroxyindoleacetaldehyde-14C and its metabolites in rat brain.
Feldstein A; Sidel CM
Int J Neuropharmacol; 1969 Jul; 8(4):347-51. PubMed ID: 5307042
[No Abstract] [Full Text] [Related]
12. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
Andrews CJ; Somerville B
Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
[No Abstract] [Full Text] [Related]
13. L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients.
Goodwin FK; Murphy DL; Brodie HK; Bunney WE
Biol Psychiatry; 1970 Oct; 2(4):341-66. PubMed ID: 4920729
[No Abstract] [Full Text] [Related]
14. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
Chase TN
Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
[No Abstract] [Full Text] [Related]
15. The common pathophysiology of monaminergic psychoses: a new hypothesis.
Tissot R
Neuropsychobiology; 1975; 1(4):243-60. PubMed ID: 775359
[TBL] [Abstract][Full Text] [Related]
16. ["Precursor-therapy" with active amines. 2. Treatment of Parkinson's disease by L-5-HTP (L-5-hydroxytryptophan)].
Sano I; Taniguchi K
Seishin Shinkeigaku Zasshi; 1971; 73(11):835-9. PubMed ID: 5316906
[No Abstract] [Full Text] [Related]
17. [Hypothetical concept: the physiopathological entity of monoaminergic psychoses].
Tissot R
Encephale; 1975; 1(4):289-339. PubMed ID: 1082812
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
[No Abstract] [Full Text] [Related]
19. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
Geissbuhler F; Bartholini G; Gaillard JM; Tissot R
Encephale; 1971; 60(3):189-209. PubMed ID: 5119348
[No Abstract] [Full Text] [Related]
20. Parkinson's disease. Modification by 5-hydroxytryptophan.
Chase TN; Ng LK; Watanabe AM
Neurology; 1972 May; 22(5):479-84. PubMed ID: 4563493
[No Abstract] [Full Text] [Related]
[Next] [New Search]
